相似文献
1
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
2
The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
J Med Genet. 1983 Oct;20(5):321-9. doi: 10.1136/jmg.20.5.321.
3
Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
Clin Pharmacol Ther. 1981 Apr;29(4):493-7. doi: 10.1038/clpt.1981.68.
4
Debrisoquine oxidation in an Australian population.
Br J Clin Pharmacol. 1986 May;21(5):465-71. doi: 10.1111/j.1365-2125.1986.tb02827.x.
5
Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
Zhongguo Yao Li Xue Bao. 1990 Jan;11(1):7-10.
6
Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
Eur J Clin Pharmacol. 1987;33(4):397-402. doi: 10.1007/BF00637637.
7
Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.
Br J Clin Pharmacol. 1989 May;27(5):613-6. doi: 10.1111/j.1365-2125.1989.tb03424.x.
8
Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
Br J Clin Pharmacol. 1990 Jan;29(1):111-5. doi: 10.1111/j.1365-2125.1990.tb03609.x.
9
Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
Br J Clin Pharmacol. 1990 Feb;29(2):244-7. doi: 10.1111/j.1365-2125.1990.tb03627.x.
10
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
Br J Clin Pharmacol. 1985 Dec;20(6):555-66. doi: 10.1111/j.1365-2125.1985.tb05112.x.
引用本文的文献
1
Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism.
Pharmacol Rev. 2024 Oct 16;76(6):1104-1132. doi: 10.1124/pharmrev.124.001173.
2
Options for treating postherpetic neuralgia in the medically complicated patient.
Ther Clin Risk Manag. 2013;9:329-40. doi: 10.2147/TCRM.S47138. Epub 2013 Aug 19.
3
Development of neuroleptic agents: pharmacogenetics and current safety issues of regulatory concern.
Dialogues Clin Neurosci. 2002 Dec;4(4):449-62. doi: 10.31887/DCNS.2002.4.4/rshah.
4
Clinically relevant genetic variations in drug metabolizing enzymes.
Curr Drug Metab. 2011 Jun;12(5):487-97. doi: 10.2174/138920011795495321.
5
Propafenone poisoning--a case report with plasma propafenone concentrations.
J Med Toxicol. 2010 Mar;6(1):37-40. doi: 10.1007/s13181-010-0037-2.
6
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000.
7
Opioid metabolism.
Mayo Clin Proc. 2009 Jul;84(7):613-24. doi: 10.1016/S0025-6196(11)60750-7.
8
Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.
Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S22. doi: 10.1186/bcr2182. Epub 2008 Dec 18.
9
Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype.
J Pharmacokinet Pharmacodyn. 2007 Apr;34(2):141-56. doi: 10.1007/s10928-006-9038-9. Epub 2006 Oct 12.
10
Drug metabolism and pharmacogenetics: the British contribution to fields of international significance.
Br J Pharmacol. 2006 Jan;147 Suppl 1(Suppl 1):S89-99. doi: 10.1038/sj.bjp.0706466.
本文引用的文献
1
Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine.
Xenobiotica. 1979 Jul;9(7):397-404. doi: 10.3109/00498257909038744.
2
The metabolism of [14C]-debrisoquine in man.
Br J Clin Pharmacol. 1979 Mar;7(3):257-66. doi: 10.1111/j.1365-2125.1979.tb00930.x.
3
Polymorphism of carbon oxidation of drugs and clinical implications.
Br Med J. 1978 Sep 2;2(6138):655-7. doi: 10.1136/bmj.2.6138.655.
4
Polymorphic hydroxylation of Debrisoquine in man.
Lancet. 1977 Sep 17;2(8038):584-6. doi: 10.1016/s0140-6736(77)91430-1.
Zotero 插件